WallStreetZenWallStreetZen

NASDAQ: MNKD
Mannkind Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MNKD stock forecasts and price targets.

MNKD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10

1 of 1

Forecast return on equity

Is MNKD forecast to generate an efficient return?

Company
-212.58%
Industry
143.83%
Market
89.52%
MNKD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNKD forecast to generate an efficient return on assets?

Company
30.38%
Industry
32.83%
MNKD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNKD earnings per share forecast

What is MNKD's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.18+83.3%
Avg 2 year Forecast
$0.20+100%
Avg 3 year Forecast
$0.31+210%
MNKD's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

MNKD revenue forecast

What is MNKD's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$323.5M+8.72%
Avg 2 year Forecast
$372.3M+25.09%
Avg 3 year Forecast
$447.4M+50.34%
MNKD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MNKD earnings growth forecast

How is MNKD forecast to perform vs Biotechnology companies and vs the US market?

Company
40.1%
Industry
10.2%
Market
15.27%
MNKD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
MNKD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
MNKD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

MNKD revenue growth forecast

How is MNKD forecast to perform vs Biotechnology companies and vs the US market?

Company
14.03%
Industry
55.79%
Market
9.73%
MNKD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MNKD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MNKD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNKD$3.77N/AN/A
LQDA$13.17$27.71+110.43%Buy
DYN$10.32$41.00+297.29%Buy
VRDN$14.72$36.00+144.57%Buy
MESO$10.44$24.00+130.00%Strong Buy
View Top Biotech Stocks

Mannkind Stock Forecast FAQ

What is MNKD's earnings growth forecast for 2025-2027?

(NASDAQ: MNKD) Mannkind's forecast annual earnings growth rate of 40.1% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.2%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.27%.

Mannkind's earnings in 2025 is $30,116,000.On average, 3 Wall Street analysts forecast MNKD's earnings for 2025 to be $55,710,892, with the lowest MNKD earnings forecast at $48,629,256, and the highest MNKD earnings forecast at $69,904,556. On average, 3 Wall Street analysts forecast MNKD's earnings for 2026 to be $60,786,570, with the lowest MNKD earnings forecast at $42,550,599, and the highest MNKD earnings forecast at $72,943,884.

In 2027, MNKD is forecast to generate $94,219,184 in earnings, with the lowest earnings forecast at $94,219,184 and the highest earnings forecast at $94,219,184.

If you're new to stock investing, here's how to buy Mannkind stock.

What is MNKD's revenue growth forecast for 2025-2027?

(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 14.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.73%.

Mannkind's revenue in 2025 is $297,595,000.On average, 3 Wall Street analysts forecast MNKD's revenue for 2025 to be $98,335,346,735, with the lowest MNKD revenue forecast at $94,918,229,680, and the highest MNKD revenue forecast at $100,610,891,998. On average, 3 Wall Street analysts forecast MNKD's revenue for 2026 to be $113,146,906,411, with the lowest MNKD revenue forecast at $101,148,853,146, and the highest MNKD revenue forecast at $123,035,057,818.

In 2027, MNKD is forecast to generate $135,978,038,321 in revenue, with the lowest revenue forecast at $126,803,825,183 and the highest revenue forecast at $145,152,251,458.

What is MNKD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MNKD) forecast ROA is 30.38%, which is lower than the forecast US Biotechnology industry average of 32.83%.

What is MNKD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MNKD) Mannkind's current Earnings Per Share (EPS) is $0.10. On average, analysts forecast that MNKD's EPS will be $0.18 for 2025, with the lowest EPS forecast at $0.16, and the highest EPS forecast at $0.23. On average, analysts forecast that MNKD's EPS will be $0.20 for 2026, with the lowest EPS forecast at $0.14, and the highest EPS forecast at $0.24. In 2027, MNKD's EPS is forecast to hit $0.31 (min: $0.31, max: $0.31).

What is MNKD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MNKD) forecast ROE is -212.58%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.